ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Strategies for T Therapy in Men with Metastatic Prostate Cancer in Clinical Practice
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 189164" data-attributes="member: 13851"><p><strong>FIG. 3. <span style="color: rgb(184, 49, 47)">PSA response to testosterone injections in a 61-year-old man with metastatic prostate cancer and nephrostomy tube, 5 years after radical prostatectomy with positive lymph nodes.</span> PSA at presentation was 31 ng/mL.<span style="color: rgb(184, 49, 47)"> (A) </span>Continuous T injections. Testosterone cypionate injections 400 mg intramuscularly were administered every 2 weeks. Note initial rise to 93 ng/mL with a subsequent decline to 51–60 ng/mL for 3–4 months before rising steadily to 185 ng/mL at 7 months. Arrow indicates the start of testosterone injections. Star indicates discontinuation of testosterone injections. <span style="color: rgb(184, 49, 47)">(B)</span> mBAT. Twelve-week cycles were initiated, consisting of 8 weeks of testosterone cypionate 400 mg intramuscularly every 2 weeks, followed by 4 weeks of daily enzalutamide 160 mg orally. Blood tests obtained at end of testosterone and enzalutamide periods. Arrow indicates the start of mBAT. PSA showed in log scale to preserve details of PSA values at nadirs. Note the upward slope of peaks and nadirs. Imaging studies showed no progression for *2 years, until April 2019 when new lesions appeared on bone scan and mBAT was discontinued. <span style="color: rgb(44, 130, 201)">mBAT, </span>modified BAT </strong></p><p>[ATTACH=full]11171[/ATTACH]</p><p>[ATTACH=full]11172[/ATTACH]</p></blockquote><p></p>
[QUOTE="madman, post: 189164, member: 13851"] [B]FIG. 3. [COLOR=rgb(184, 49, 47)]PSA response to testosterone injections in a 61-year-old man with metastatic prostate cancer and nephrostomy tube, 5 years after radical prostatectomy with positive lymph nodes.[/COLOR] PSA at presentation was 31 ng/mL.[COLOR=rgb(184, 49, 47)] (A) [/COLOR]Continuous T injections. Testosterone cypionate injections 400 mg intramuscularly were administered every 2 weeks. Note initial rise to 93 ng/mL with a subsequent decline to 51–60 ng/mL for 3–4 months before rising steadily to 185 ng/mL at 7 months. Arrow indicates the start of testosterone injections. Star indicates discontinuation of testosterone injections. [COLOR=rgb(184, 49, 47)](B)[/COLOR] mBAT. Twelve-week cycles were initiated, consisting of 8 weeks of testosterone cypionate 400 mg intramuscularly every 2 weeks, followed by 4 weeks of daily enzalutamide 160 mg orally. Blood tests obtained at end of testosterone and enzalutamide periods. Arrow indicates the start of mBAT. PSA showed in log scale to preserve details of PSA values at nadirs. Note the upward slope of peaks and nadirs. Imaging studies showed no progression for *2 years, until April 2019 when new lesions appeared on bone scan and mBAT was discontinued. [COLOR=rgb(44, 130, 201)]mBAT, [/COLOR]modified BAT [/B] [ATTACH type="full"]11171[/ATTACH] [ATTACH type="full"]11172[/ATTACH] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Strategies for T Therapy in Men with Metastatic Prostate Cancer in Clinical Practice
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top